Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The biotech, renowned for its pioneering development of vaccines based on ...

Benzinga's options scanner just detected over 16 options trades for Moderna (NASDAQ:MRNA) summing a total amount of $1,134,726. At the same time, our algo caught 10 for a total amount of 1,113,875.

Looking at options history for Moderna (NASDAQ:MRNA) we detected 26 trades. If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish ...

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural for investors to wonder about where the biotech will go in the near ...

Moderna (NASDAQ:MRNA) stock drops ~5% as its Q4 2024 results show revenue beat but earnings miss expectations. Read more here ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19 ...

Investors with a lot of money to spend have taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the positions showed up on publicly ...

Our analysis of options history for Moderna (NASDAQ:MRNA) revealed 28 unusual trades. Delving into the details, we found 17% of traders were bullish, while 64% showed bearish tendencies.

Despite a significant revenue decline, Moderna Inc (MRNA) focuses on strategic program prioritization and cost management to ...

Biotechnology company Moderna Inc. (NASDAQ: MRNA) gained the spotlight in the medical sector as a leader in the race toward a COVID-19 vaccine. Its messenger RNA (mRNA) technology garnered acclaim ...

Our analysis of options history for Moderna (NASDAQ:MRNA) revealed 31 unusual trades. Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies.

Moderna (MRNA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives ...